https://orcid.org/0000-0002-0095-2293
Figures
Abstract
Background
Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine.
Methods
This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as “effective” in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study.
Results
Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007–0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129–0.966).
Citation: Kanbayashi Y, Shimizu M, Ishizuka Y, Sawa S, Yabe K, Uchida M (2022) Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis. PLoS ONE 17(12): e0278823. https://doi.org/10.1371/journal.pone.0278823
Editor: Masahiko Sumitani, University of Tokyo, JAPAN
Received: May 21, 2022; Accepted: November 25, 2022; Published: December 9, 2022
Copyright: © 2022 Kanbayashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data cannot be shared publicly because the data contain potentially identifying or sensitive patient information. However, data are available from the institutional medical ethics review committee at Osaka Medical Pharmaceutical University (contact via rinri@ompu.ac.jp) for researchers who meet the criteria for access to confidential data.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL) [1,2]. OIC is common among patients with advanced cancers, with a prevalence of approximately 51–87% among patients receiving opioids for pain management [1–4]. Naldemedine is the newest orally available peripheral-acting μ-opioid receptor antagonist (PAMORA) approved for OIC treatment in adult patients [5–7]. Naldemedine improves OIC by binding to opioid receptors in the gastrointestinal tract and antagonizing opioid analgesics [5]. The analgesic effects of many opioid analgesics are expressed mainly via the central μ-opioid receptor [1,2,5]. Naldemedine is a PAMORA designed so as not to inhibit the action of opioid analgesics in the central nervous system [5–7]. In phase III trials, naldemedine was more effective than placebo for increasing the frequency of spontaneous bowel movements among patients with OIC and cancer pain [6,7]. Naldemedine has also been shown to improve patient-rated constipation-related symptoms and QOL [6–8].
However, in daily clinical practice, some advanced cancer patients show insufficient OIC control even while receiving naldemedine. We showed that in our previous study, OIC was poorly controlled in 39.6% of patients, even when naldemedine was administered [9]. In addition, direct evidence remains lacking regarding the comparative efficacy of naldemedine compared with previous laxative treatments (osmotic laxative [e.g., magnesium and sulfate salts, lactulose and polyethylene glycol], stimulant laxative [e.g., anthranoid plant compounds, bisacodyl] or intestinal secretagogues [lubiprostone]) and PAMORAs (e.g., methylnaltrexone or naloxegol).
Previous studies have clarified that risk factors for constipation include female sex, advanced age, medications (e.g., anticholinergics, antipsychotics), diets, comorbidities, and mental states [10–12]. We also showed that the risk factors of OIC were high body mass index (BMI), chemotherapy including a taxane within 1 month of evaluation of laxative effect, no use of naldemedine, and addition or switching due to insufficient prior laxatives in advanced cancer patients [9]. Lavan et al. clarified in an observational study of an oncological population that constipation occurred in 20% of patients [13]. In that study, causative medications included systemic anticancer therapies (53.3%) and opioids (17.3%) [13]. Although a previous study clarified use of naldemedine within 2 days of opioid initiation was a predictor of efficacy of naldemedine, including patients with chronic pain, information remains limited for cancer patients [14,15]. This subgroup analysis of our previous study [9] was therefore undertaken to identify predictors of non-response to naldemedine prescribed for OIC among cancer patients, to help guide future strategies toward improving QOL in advanced cancer patients receiving pain treatment with opioids.
Patients and methods
Study period and participants
This subgroup analysis analyzed 127 cancer patients with cancer pain who were prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. Patients who discontinued naldemedine within 2 days, were discharged within 2 days after starting naldemedine, or lacked data on defecation for the first 3 days after naldemedine prescription (missing data) were excluded. The data used were from the group of patients who received naldemedine in our previous study [9].
Ethics and consent
All study protocols were approved by the Medical Ethics Review Committee at Seirei Hamamatsu General Hospital (approval no. 3310) and the Faculty of Pharmacy at Osaka Medical Pharmaceutical University (approval no. 0088). All procedures were performed in accordance with the ethical standards of Seirei Hamamatsu General Hospital, the Institutional Medical Ethics Review Committee at Osaka Medical Pharmaceutical University and the 1964 Declaration of Helsinki and its later amendments. Given the retrospective nature of this work, the need to obtain informed consent was waived for the individual participants included in the study, in accordance with the standards of the Seirei Hamamatsu General Hospital and Osaka Medical Pharmaceutical University of Medicine Institutional Medical Ethics Review Committee.
Extraction of variables
Variables associated with potential risk factors for OIC were extracted from electronic medical records and used for regression analysis. Variables extracted were factors considered as potentially affecting OIC based on previous studies [1,9–13] or clinically rational mechanisms, including demographic data (age, BMI, body surface area [BSA]), clinical data (Eastern Cooperative Oncology Group performance status [ECOG-PS], and stage of cancer), medication-related data (chemotherapy administered within 1 month of the evaluation of naldemedine effect, anti-cancer drugs administered within 1 month of the evaluation of naldemedine effect, types of opioids, daily dose of opioid in milligrams of morphine-equivalents, concomitant laxative, concomitant use of the serotonin 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, naldemedine prescription within 2 days of opioid initiation, and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives), and cancer type.
Outcomes measured
The presence of OIC was defined based on Rome IV diagnostic criteria [2] by the attending physician, who then prescribed naldemedine. Details of the Rome IV diagnostic criteria used for the diagnosis of OIC in this study have been published previously [16,17].
The retrospective nature of this study meant that insufficient data were able to be extracted regarding stool properties after prescribing naldemedine. Naldemedine was thus evaluated as “effective” in cases where the number of defecations increased at least once within the first 3 days after starting naldemedine.
Statistical analysis
This study used logistic regression analysis, with the response Y being a binary categorical variable (naldemedine effective = 1; naldemedine not effective = 0) evaluated simultaneously with multiple predictors for OIC = X.
Independent variables were analyzed for multicollinearity (correlation coefficient |r| ≥ 0.7), since correlations among variables can lead to unreliable and unstable results of regression analyses. First, univariate logistic regression analyses between outcomes and each potential independent variable were performed. Subsequently, a multivariate logistic regression model was constructed by employing those candidate variables showing values of P < 0.20 in univariate regression or selected based on previous studies. Whether a difference in the effect of naldemedine was seen according to the concomitant use of opioids or laxatives was also analyzed. Wilcoxon/Kruskal–Wallis test was used to identify significant differences between groups.
For all statistical analyses, values of P < 0.05 (two-tailed) were considered significant. All analyses were conducted using JMP Pro® version 16.2 (SAS Institute, Cary, NC, USA).
Results
Of the 127 patients extracted, 106 patients were evaluated in this study (Fig 1). A total of 21 patients were excluded from this study due to discontinuation of naldemedine within 2 days (n = 1), discharge within 2 days (n = 1) or missing data (n = 19). Table 1 presents the clinical characteristics of the remaining 106 enrolled patients. Potential variables related to OIC and the results of univariate logistic regression analyses are shown in Table 2. The response rate to naldemedine was 60.4% (64/106). Univariate analyses only extracted “chemotherapy with taxane within 1 month of evaluation of naldemedine effect” as a significant factor.
A total of 21 patients were excluded from this study due to discontinuation of naldemedine within 2 days (n = 1), discharge within 2 days (n = 1) or missing data (n = 19).
Multicollinearity was detected in BMI and BSA. BMI, which was considered the most clinically relevant for constipation, was used for analysis. The selection procedure using factors showing values of P < 0.20 in univariate regression or selection based on previous studies identified the following variables: BMI, chemotherapy with taxane within 1 month of evaluation of naldemedine effect, daily dose of opioid, use of naldemedine within 2 days of opioid initiation, and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives. Neither platinum-based nor fluorouracil-based protocols other than taxanes were extracted as significant factors in the univariate analysis.
Multivariate logistic regression analysis was performed using these variables. Significant factors identified included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007–0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129–0.966) (Table 3). Since the ORs were less than 1.0, both factors were extracted as factors associated with non-response to naldemedine.
No differences were evident in the effect of naldemedine among types of concomitant opioids (P = 0.658) or according to the concomitant use of laxatives (P = 0.536).
Discussion
The results of this study showed that OIC was poorly controlled when taxane chemotherapy was administered within 1 month of evaluation of the naldemedine effect or with addition of or switching to naldemedine due to insufficient efficacy of prior laxatives. Our results are similar to those of our previous study [9], suggesting that patients prone to developing OIC may also be non-responsive to naldemedine. This study also showed that the effect of naldemedine was not different types of concomitant opioids or according to the concomitant use of laxatives.
Taxanes are anticancer drugs that have an adverse effect of constipation due to neuropathy [18]. Taxane-induced neuropathy persists for a prolonged period in clinical practice. If taxanes were administered within 1 month of evaluation of naldemedine effect, those adverse effects may still be present. As naldemedine is a PAMORA, control of constipation caused by taxanes may be difficult. Taxane-induced neuropathy may also affect the enteric nervous system and may decrease intestinal motility. Colonic irritant laxatives such as castor oil may thus be preferable. If paralysis of the intestinal tract occurs, intestinal decompression or other measures may be necessary. This point needs further validation. On the other hand, naldemedine is primarily metabolized by cytochrome P450 3A4 (CYP3A4) to form nor-naldemedine [19]. A previous study showed that coadministration of a P-glycoprotein inhibitor, CYP3A inhibitors, and a CYP3A inducer had notable effects on the pharmacokinetics of naldemedine [19]. In this study, some patients were receiving taxane chemotherapy at the time of evaluation of naldemedine effect. Enzyme systems such as CYP3A4 participate in metabolism of taxanes such as paclitaxel and docetaxel [20,21]. Although no reports have described drug-drug interactions between naldemedine and taxanes, the possibility of reduced naldemedine effects due to drug-drug interactions needs to be kept in mind, particularly in patients undergoing chemotherapy with taxanes. This point needs further verification using data from daily clinical practice. In recent years, new opioid prescriptions are often made by oncologists during chemotherapy. Thus, this information is useful for physicians who examine patients with breast, ovarian, or lung cancers who are often prescribed taxanes, and may help to improve QOL for patients. In particular, since these cancer patients are often treated on an outpatient basis, patients need to receive explanations that they should carefully monitor their own bowel movements at home. This information will also prove useful for pharmacists in providing medication guidance. However, the number of patients treated with taxanes in this study was small (9 patients). Therefore, further studies with larger numbers of patients are needed to establish evidence.
Addition of or switching due to insufficient prior laxatives was also extracted as a factor associated with non-response to naldemedine being prescribed for OIC. Naldemedine is a PAMORA, and the mechanism of action suggests that efficacy may be greater for a shorter duration of opioid exposure. Administration of naldemedine from the initiation of opioids may also reduce the risk of developing the opioid-withdrawal symptoms that can be seen when naldemedine is started during opioid administration [22,23]. On the other hand, the factor “naldemedine prescription within 2 days of opioid initiation” was not extracted as a significant factor in the present study. Some patients were undergoing chemotherapy at the time of evaluation of naldemedine effect. Recently, the serotonin 5-HT3 receptor antagonists have been commonly used in preventing chemotherapy-induced nausea and vomiting. However, the serotonin 5-HT3 receptor antagonist may have also acted on serotonin receptors in the intestine and decreased intestinal motility [24]. Thus, laxative therapy is often indicated. Although not significant in this study, it has been suggested that concomitant use of the serotonin 5-HT3 receptor antagonists is a nonresponding factor of naldemedine. The guidelines for OIC also suggest that classic laxatives should be used first, with the use of novel constipation treatments or PAMORA recommended only if the effects prove insufficient [25,26]. The appropriate timing of naldemedine administration needs to be verified in the future.
Although BMI was not a significant factor, our results showed that naldemedine tended to be ineffective for patients with higher BMI. Previous studies have reported obesity as a risk factor for constipation [27]. The results of this study were thus consistent with previous findings, and further study of this issue is warranted.
Daily dose of opioid was also not extracted as a significant factor. Roeland et al. showed a weak to absent association between total daily opioid dose and constipation in patients with cancer [28]. This result was again consistent with our findings. Our results suggest that OIC can be controlled with naldemedine regardless of the opioid dose.
OIC has a considerable effect on QOL for cancer patients receiving opioids. Cancer patients may occasionally discontinue opioid use due to OIC and endure pain. Patients with advanced cancer are also likely to experience severe distress, reduced work productivity, poor QOL, and increased healthcare utilization [1,29]. Several studies have reported improved QOL for cancer patients with improvements in constipation [30,31]. Clinicians should thus be alert to the occurrence of OIC and work to improve this symptom. The identification of factors associated with non-response to naldemedine being administered for OIC in this study may therefore help improve QOL for cancer patients.
In the present study, no difference in the effect of naldemedine was seen among types of concomitantly used opioids or laxatives. Among opioids, fentanyl has been reported to have a lower risk of constipation as a side effect [32]. However, the type of concomitantly used opioids in this study did not appear to affect the efficacy of naldemedine. Concomitant use of laxatives was also not found to have any effect on the efficacy of naldemedine.
Several limitations to the current study need to be considered. First, the retrospective nature of the study may have decreased the validity of the data obtained. That is, potential confounding, selection, and information biases could not be fully excluded in this study. Second, completely controlling for factors affecting constipation was difficult, given the wide variety of such factors, including medications (e.g., anticholinergics and antipsychotics), diet, comorbidities (e.g., cerebrovascular diseases), and mental state. Third, since this study was performed at a single institute, and it only examined a relatively small number of patients, some degree of selection bias would have been present. The present findings therefore need to be confirmed in further studies. Nevertheless, these results may help improve QOL among patients with advanced cancer and cancer pain.
In conclusion, administration of a chemotherapeutic regimen that included taxanes within one month before the evaluation of naldemedine effect and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives were identified as factors associated with non-response to naldemedine being administered for OIC in cancer patients.
Acknowledgments
We wish to thank all the patients and medical staff at Seirei Hamamatsu General Hospital who participated in this study.
References
- 1. Almouaalamy N.A. Opioid-Induced Constipation in Advanced Cancer Patients. Cureus. 2021;13:e14386. pmid:33850679.
- 2. Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O’Brien T, Morlion B, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019;7:7–20. pmid:30788113.
- 3. Krashin D, Murinova N, Jumelle P, Ballantyne J. Opioid risk assessment in palliative medicine. Expert Opin Drug Saf. 2015; 14:1023–33. pmid:26084635.
- 4. Mercadante S. Emerging drugs for cancer-related pain. Support Care Cancer. 2011; 19:1887–93. pmid:21938596.
- 5. Markham A. Naldemedine: First Global Approval. Drugs. 2017;77:923–927. pmid:28466424.
- 6. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol. 2017; 35:3859–3866. pmid:28968171.
- 7. Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017; 2:555–564. pmid:28576452.
- 8. Hanson B, Siddique SM, Scarlett Y, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019; 156:229-253.e5. pmid:30337104.
- 9. Kanbayashi Y, Ishizuka Y, Shimizu M, Sawa S, Yabe K, Uchida M. Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis. Support Care Cancer. 2022. pmid:35355120.
- 10. Chen Z, Peng Y, Shi Q, Chen Y, Cao L, Jia J, et al. Prevalence and Risk Factors of Functional Constipation According to the Rome Criteria in China: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2022; 9:815156. pmid:35252254.
- 11. Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scotté F, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29 Suppl 4: iv111–iv125. pmid:32169221.
- 12. Pinto CFCS, Oliveira PDCM, Fernandes OMFSO, Padilha JMDSC, Machado PAP, Ribeiro ALA, et al. Nonpharmacological Clinical Effective Interventions in Constipation: A Systematic Review. J Nurs Scholarsh. 2020; 52:261–269. pmid:32323474.
- 13. Lavan AH, O’Mahony D, Buckley M, O’Mahony D, Gallagher P. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. Oncologist. 2019;24:e968–e977. pmid:30833488.
- 14. Dzierżanowski T, Mercadante S. Constipation in Cancer Patients—an Update of Clinical Evidence. Curr Treat Options Oncol. 2022;23:936–950. pmid:35441979.
- 15. Kanbayashi Y, Amaya F, Ueno H, Tabuchi Y, Ishikawa T, Takayama K, et al. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis. Pharmazie. 2021; 76:175–178. pmid:33849704.
- 16. Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016: S0016-5085(16)00180-3. pmid:27144634.
- 17. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020; 158:1262-1273.e3. pmid:31917991.
- 18. Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, et al. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Oncologist. 2019; 24:762–771. pmid:30552158.
- 19. Fukumura K, Kawaguchi N, Ishibashi T, Kubota R, Tada Y, Ogura E. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. Clin Drug Investig. 2020; 40:529–540. pmid:32323104.
- 20. van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol. 2019; 84:487–499. pmid:31309254.
- 21. Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations. Eur J Pharmacol. 2013; 717:40–6. pmid:23660368.
- 22. Rekatsina M, Paladini A, Drewes AM, Ayob F, Viswanath O, Urits I, et al. Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review. Cureus. 2021;13:e16201. pmid:34367804.
- 23. Ishii K, Yamashita H, Yamaguchi M, Komatsu Y, Ryu E, Morishita S, et al. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis. Intern Med. 2020; 59:293–296. pmid:31534081.
- 24. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf. 2003; 26:227–59. pmid:12608887.
- 25. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019; 156:218–226. pmid:30340754.
- 26. Müller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, et al. Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. Pain Med. 2017; 18:1837–1863. pmid:28034973.
- 27. Yurtdaş G, Acar-Tek N, Akbulut G, Cemali Ö, Arslan N, Beyaz Coşkun A, et al. Risk Factors for Constipation in Adults: A Cross-Sectional Study. J Am Coll Nutr. 2020; 39:713–719. pmid:32077808.
- 28. Roeland EJ, Sera CJ, Ma JD. More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. Support Care Cancer. 2020; 28:1793–1797. pmid:31332514.
- 29. Rumman A, Gallinger ZR, Liu LWC. Opioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment. Expert Review of Quality of Life in Cancer Care. 2016; 1:25–35. https://doi.org/10.1080/23809000.2016.1131595.
- 30. Argoff CE. Opioid-induced Constipation: A Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting μ-Opioid Receptor Antagonists. Clin J Pain. 2020; 36:716–722. pmid:32554978.
- 31. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018; 29:1461–1467. pmid:32151367.
- 32. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;2013:CD010270. pmid:24096644.